Literature DB >> 20105077

Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women.

Howard Minkoff1, Ye Zhong, Robert D Burk, Joel M Palefsky, Xiaonan Xue, D Heather Watts, Alexandra M Levine, Rodney L Wright, Christine Colie, Gypsyamber D'Souza, L Stewart Massad, Howard D Strickler.   

Abstract

BACKGROUND: The impact of highly active antiretroviral therapy (HAART) on the natural history of human papillomavirus (HPV) remains uncertain following conflicting reports. Prior studies, however, did not consider patients' adherence to their regimens or HAART effectiveness (viral suppression).
METHODS: Human immunodeficiency virus (HIV)-positive women (N = 286) who initiated HAART during follow-up in a prospective cohort were assessed semiannually for HPV infection (by polymerase chain reaction) and squamous intraepithelial lesions (SILs). Adherence was defined as use of HAART as prescribed > or = 95% of the time, and effective HAART was defined as suppression of HIV replication. The prevalence, incident detection, and clearance of HPV infection and/or SILs before versus after HAART initiation were compared (using women as their own comparison group).
RESULTS: HAART initiation among adherent women was associated with a significant reduction in prevalence (odds ratio, 0.60 [95% confidence interval {CI}, 0.44-0.81]; P = .001), incident detection of oncogenic HPV infection (hazard ratio [HR], 0.49 [95% CI, 0.30-0.82]; P = .006), and decreased prevalence and more rapid clearance of oncogenic HPV-positive SILs (HR, 2.35 [95% CI, 1.07-5.18]; P = .03). Effects were smaller among nonadherent women. The associations of HPV infection and/or SILs with HAART effectiveness were fairly similar to those with HAART adherence.
CONCLUSION: Effective and adherent HAART use is associated with a significantly reduced burden of HPV infection and SILs; this may help explain why rates of cervical cancer have not increased during the HAART era, despite greater longevity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20105077      PMCID: PMC2818607          DOI: 10.1086/650467

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  29 in total

1.  Presenting plasma HIV RNA level and rate of CD4 T-cell decline.

Authors:  Viviane D Lima; Robert S Hogg; Julio S G Montaner
Journal:  JAMA       Date:  2007-02-28       Impact factor: 56.272

2.  Marginal and mixed-effects models in the analysis of human papillomavirus natural history data.

Authors:  Xiaonan Xue; Stephen J Gange; Ye Zhong; Robert D Burk; Howard Minkoff; L Stewart Massad; D Heather Watts; Mark H Kuniholm; Kathryn Anastos; Alexandra M Levine; Melissa Fazzari; Gypsyamber D'Souza; Michael Plankey; Joel M Palefsky; Howard D Strickler
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01       Impact factor: 4.254

3.  Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection.

Authors:  Benigno Rodríguez; Ajay K Sethi; Vinay K Cheruvu; Wilma Mackay; Ronald J Bosch; Mari Kitahata; Stephen L Boswell; W Christopher Mathews; David R Bangsberg; Jeffrey Martin; Christopher C Whalen; Scott Sieg; Suhrida Yadavalli; Steven G Deeks; Michael M Lederman
Journal:  JAMA       Date:  2006-09-27       Impact factor: 56.272

4.  Impact of drug abuse treatment modalities on adherence to ART/HAART among a cohort of HIV seropositive women.

Authors:  Farzana Kapadia; David Vlahov; Yingfeng Wu; Mardge H Cohen; Ruth M Greenblatt; Andrea A Howard; Judith A Cook; Lakshmi Goparaju; Elizabeth Golub; Jean Richardson; Tracey E Wilson
Journal:  Am J Drug Alcohol Abuse       Date:  2008       Impact factor: 3.829

5.  Evolution of cervical cytologic changes among HIV-infected women with normal cytology in the HAART era.

Authors:  Guillem Sirera; Sebastià Videla; Raquel López-Blázquez; Mariona Llatjos; Antoni Tarrats; Eva Castellà; Nuria Grane; Carmen Alcalde; Cristina Tural; Celestino Rey-Joly; Bonaventura Clotet
Journal:  AIDS Res Hum Retroviruses       Date:  2007-08       Impact factor: 2.205

6.  Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

Authors:  Roberto Ortiz; Edwin Dejesus; Homayoon Khanlou; Evgeniy Voronin; Jan van Lunzen; Jaime Andrade-Villanueva; Jan Fourie; Sandra De Meyer; Martine De Pauw; Eric Lefebvre; Tony Vangeneugden; Sabrina Spinosa-Guzman
Journal:  AIDS       Date:  2008-07-31       Impact factor: 4.177

7.  The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology.

Authors:  Pangaja Paramsothy; Denise J Jamieson; Charles M Heilig; Paula C Schuman; Robert S Klein; Keerti V Shah; Anne M Rompalo; Susan Cu-Uvin; Ann Duerr
Journal:  Obstet Gynecol       Date:  2009-01       Impact factor: 7.661

8.  AIDS-related cancer and severity of immunosuppression in persons with AIDS.

Authors:  Robert J Biggar; Anil K Chaturvedi; James J Goedert; Eric A Engels
Journal:  J Natl Cancer Inst       Date:  2007-06-12       Impact factor: 13.506

Review 9.  HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy.

Authors:  Hugo De Vuyst; Flavia Lillo; Nathalie Broutet; Jennifer S Smith
Journal:  Eur J Cancer Prev       Date:  2008-11       Impact factor: 2.497

10.  The relationship between cocaine use and human papillomavirus infections in HIV-seropositive and HIV-seronegative women.

Authors:  Howard Minkoff; Ye Zhong; Howard D Strickler; D Heather Watts; Joel M Palefsky; Alexandra M Levine; Gypsyamber D'Souza; Andrea A Howard; Michael Plankey; L Stewart Massad; Robert Burk
Journal:  Infect Dis Obstet Gynecol       Date:  2008
View more
  67 in total

1.  Prevalence of Anal HPV and Anal Dysplasia in HIV-Infected Women From Johannesburg, South Africa.

Authors:  Bridgette J Goeieman; Cynthia S Firnhaber; Eefje Jong; Pam Michelow; Patricia Kegorilwe; Avril Swarts; Anna-Lise Williamson; Bruce Allan; Jennifer S Smith; Timothy J Wilkin
Journal:  J Acquir Immune Defic Syndr       Date:  2017-07-01       Impact factor: 3.731

Review 2.  Human papillomavirus in the HIV-infected host: epidemiology and pathogenesis in the antiretroviral era.

Authors:  Cristina Brickman; Joel M Palefsky
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

3.  Oral Lopinavir Use and Human Papillomavirus Infection in HIV-Positive Women.

Authors:  Cecile D Lahiri; Katherine B Dugan; Xianhong Xie; Laura Reimers; Robert D Burk; Kathryn Anastos; Leslie Stewart Massad; Isam-Eldin Eltoum; Xiaonan Xue; Gypsyamber DʼSouza; Lisa Flowers; Joel M Palefsky; Lisa Rahangdale; Howard D Strickler; Ighovwerha Ofotokun
Journal:  J Acquir Immune Defic Syndr       Date:  2015-10-01       Impact factor: 3.731

4.  Persistence of memory B-cell and T-cell responses to the quadrivalent HPV vaccine in HIV-infected children.

Authors:  Adriana Weinberg; Sharon Huang; Anna-Barbara Moscicki; Afred Saah; Myron J Levin
Journal:  AIDS       Date:  2018-04-24       Impact factor: 4.177

Review 5.  Incidence and progression of cervical lesions in women with HIV: a systematic global review.

Authors:  Sheri A Denslow; Anne F Rositch; Cynthia Firnhaber; Jie Ting; Jennifer S Smith
Journal:  Int J STD AIDS       Date:  2013-08-29       Impact factor: 1.359

6.  Incidence of cervical precancers among HIV-seropositive women.

Authors:  L Stewart Massad; Xianhong Xie; Gypsyamber D'Souza; Teresa M Darragh; Howard Minkoff; Rodney Wright; Christine Colie; Lorraine Sanchez-Keeland; Howard D Strickler
Journal:  Am J Obstet Gynecol       Date:  2014-12-10       Impact factor: 8.661

7.  Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study.

Authors:  Alison G Abraham; Gypsyamber D'Souza; Yuezhou Jing; Stephen J Gange; Timothy R Sterling; Michael J Silverberg; Michael S Saag; Sean B Rourke; Anita Rachlis; Sonia Napravnik; Richard D Moore; Marina B Klein; Mari M Kitahata; Gregory D Kirk; Robert S Hogg; Nancy A Hessol; James J Goedert; M John Gill; Kelly A Gebo; Joseph J Eron; Eric A Engels; Robert Dubrow; Heidi M Crane; John T Brooks; Ronald J Bosch; Howard D Strickler
Journal:  J Acquir Immune Defic Syndr       Date:  2013-04-01       Impact factor: 3.731

8.  The impact of HIV viral control on the incidence of HIV-associated anal cancer.

Authors:  Elizabeth Y Chiao; Christine M Hartman; Hashem B El-Serag; Thomas P Giordano
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-15       Impact factor: 3.731

9.  Association between smoking and size of anal warts in HIV-infected women.

Authors:  H N Luu; E S Amirian; R P Beasley; L Piller; W Chan; M E Scheurer
Journal:  Int J STD AIDS       Date:  2012-11       Impact factor: 1.359

Review 10.  Cancer prevention in HIV-infected populations.

Authors:  Priscila H Goncalves; Jairo M Montezuma-Rusca; Robert Yarchoan; Thomas S Uldrick
Journal:  Semin Oncol       Date:  2015-09-08       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.